Courtney Andersen studies the role of estrogen receptor-alpha in ovarian cancer.
Chris Barnes investigates the structural details by which transcription factor activity regulates RNA Polymerase II during the universal process of eukaryotic gene expression.
Soma Jobaggy studies nitrated fatty acid pharmacology and the antioxidant response in hypertensive end-organ damage.
Allison Nagle studies growth factor receptor signaling in breast cancer.
Jeffrey S. Isenberg, MD
Associate Professor, Medicine
E1258 Biomedical Science Tower
Pittsburgh, PA 15261

Email:
jsi5@pitt.edu
Phone: 412-383-5424

Fax: 412-648-5980


Education

BA, University of Pennsylvania, 1982
MPH, Tulane University of Public Health and Tropical Medicine, 1985
MD, Tulane University School of Medicine, 1986

Photo of Jeffrey S. Isenberg, MD

Dr. Isenberg's research interests have centered on the need to enhance tissue blood flow, perfusion and wound healing, and stem from his background as a reconstructive microsurgeon. As a clinician, the focus of his work was the development and application of novel autologous composite tissue units for closure of complex wounds. In addition to anatomical research in tissue vascular anatomy, he studied the ability of complex tissue reconstructive units to withstand stress injuries. He now studies the molecular aspect of blood flow and perfusion, and has recently discovered a novel inhibitory pathway that blocks physiologic nitric oxide (NO) signaling. NO is one of the body's central means of promoting blood flow through its ability to dilate arteries, improve cardiac contractility and decrease platelet interactions and clotting. Recently he made the startling discovery that a matrix protein, thrombspondin-1 (TSP1), completely inhibits NO-driven events in vascular cells by blocking activation of multiple points in the canonical NO path including eNOS, sGC and PKG. This process requires the interaction of TSP1 with the cell surface receptor CD47. He has found that this inhibitory pathway limits NO signaling both in cells and in vivo. In turn, by blocking this pathway it is possible to enhance NO signaling, thereby increasing tissue blood flow and perfusion, survival to ischemia and I/R injury, and preventing platelet thrombosis. Recent research in the lab has uncovered a critical role for TSP1 through its receptor CD47, in acute regulation of cardiovascular dynamics, hemostasis, mitochondrial homeostasis and responses to high dose of radiation.

 





Important Publications
Bauer EM, Y Qin, TW Miller, RW Bandle, G Csanyi, PJ Pagano, PM Bauer, J Schnermann, DD Roberts and JS Isenberg.  Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation.  Cardiovasc Res 88:471-481, 2010.
Maxhimer JB, DR Soto-Pantoja, LA Ridnour, HB Shih, WG Degraff, M Tsokos, DA Wink, JS Isenberg and DD Roberts.  Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling.  Transl Med 1:3ra7, 2009.
Isenberg JS, G Martin-Manso, JB Maxhimer and DD Roberts.  Regulation of nitric oxide signaling by thrombospondin 1:  Implications for anti-angiogenic therapies.  Nat Rev Cancer 9:182-194, 2009.
Isenberg JS, MJ Romeo, C Yu, CK Yu, K Nghiem, J Monsale, ME Rick, DA Wink, WA Frazier and DD Roberts.  Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling.  Blood 111:613-623, 2008.
Isenberg JS, MJ Romeo, M Abu-Asab, M Tsokos, A Oldenborg, L Pappan, DA Wink, WA Frazier and DD Roberts.  Increasing survival of ischemic tissue by targeting CD47.  Circ Res 100:712-720, 2007.
Isenberg JS, F Hyodo, K Matsumoto, MJ Romeo, M Abu-Asab, M Tsokos, P Kuppusamy, DA Wink, MC Krishna and DD Roberts.  Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation.  Blood 109:1945-1952, 2007.
Isenberg JS, F Hyodo, LK Pappan, M Abu-Asab, M Tsokos, MC Krishna, WA Frazier and DD Roberts.  Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia.  Arterioscler Thromb Vasc Biol 27:2582-2588, 2007.
Isenberg JS, LA Ridnour, EM Perruccio, MG Espey, DA Wink and DD Roberts.  Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner.  Proc Natl Acad Sci USA 102:13141-13146, 2005.

STUDENT NEWS


UPCOMING EVENTS
11/27/2017 8:30 AM Molecular Pharmacology Journal Club
Lloyd Harvey


11/30/2017 12:00 PM Pharmacology & Chemical Biology Seminar Series
Jeffrey L. Brodsky, Ph.D.


12/4/2017 8:30 AM Molecular Pharmacology Journal Club
Andrew Lamade


Pharmacology and Chemical Biology Event Calendar

Program Achievements

Molecular Pharmacology Graduate Program Ranked #2 in National Research Council Rankings

Molecular Pharmacology Graduate Program Ranked #2 in Faculty Scholarly Productivity Index


Outcomes:  Time to disseration, last five graduating clasess:  4.5 years, Completion Rate: 84.8%

Ranked #12 in National of Institute of Health funding of departments of Pharmacology

Ranked in the top 15 in funding for twenty consecutive years




Back to Top